F o r H e a l t h & W e l l n e s s T H E U N S U N G I N G R E D I E N T S While FMC does not  manufacture drugs, vitamins  or nutritional supplements,  we have long been a leader  in helping the pharmaceutical  industry create and market  consumable products from  renewable biopolymers. Our  pharmaceutical customers  represent a significant segment  of our Specialty Chemicals  business – and we take  seriously our role in providing  the right chemistry to serve  their consumers’ essential  health needs. If we don’t make pharma- ceuticals, what  do  we make?  One category is excipients –  inactive substances that bind  a product together, add bulk to  high-potency active ingredients,  speed or slow absorption in the  body, or activate the product’s  dissolving process. Excipients  commonly take the form of  tablet binders, suspension  aids, super-disintegrants and  controlled-release coatings. Our Avicel ®  brand continues  to be the leading binder of dry tablets.  We also have developed and  commercialized new soft  capsule technology that utilizes  carrageenan. These new soft  capsules are being used for  vitamins and other supplements.  Today we are in the advanced  development stages of new  alginate-based soft capsules  for pharmaceuticals. And  our ultrapure biopolymers  have numerous biomedical  applications, including tissue  engineering, cell encapsulation,  and medical devices. FMC lithium plays a role, too,  as it is used for synthesizing  cholesterol-reducing drugs. We  have constructed a butyllithium  plant in India and one in China  to serve the pharmaceutical  manufacturing industry in  these expanding markets. And  lithium carbonate is the active  ingredient in the preferred  treatment of bipolar disorder. Our chemistry is largely taken  for granted by most consumers  but it is an essential component  in the practical consumption  of many pharmaceuticals. For  FMC, demand for this chemistry  parallels consumers’ ever- increasing health consciousness  and the need for medicines  to manage acute or chronic  pain, particularly as average life  spans continue to rise. Coupled  with demand growth in rapidly  developing economies, the  market indicators for this sector  are highly favorable. Today we are investing in our  core business to maintain  our position as a high-quality,  premium supplier. We are  adding new capacity and new  capabilities to improve our  service and speed to market for our customers. FMC Corporation | 2010 Annual Report 15